January 2022 Newsletter
January 26, 2022
Controlled Substance License
We’re excited to start 2022 strong by receiving a Controlled Substance License from the state of Indiana.
This will benefit clients studying and/or developing any Class 1 (Scheduled 1) controlled substance such as cannabinoids, psilocybin, and related compounds for their therapeutic potential.
For the first time in 50 years, NIH recently awarded Johns Hopkins Medicine a grant to research psilocybin on tobacco addiction https://tinyurl.com/4v4duu3k. We're proud of expanding our capabilities and credentials for the benefit of our clients.
Expanded Yeast Expression
Helix expands its yeast expression capabilities with the new Microfluidics M-110P system. This allows us to expand expression to yeast, process larger volumes of cells, and carry out more gentle cell lysis which keeps proteins soluble increasing yields. We're excited to strengthen our infrastructure for the benefit of our clients. Exciting times!
Did you know... Our services cover from gene construct to protein expression/protein synthesis to protein structure elucidation (Cryo-EM/crystallography)? If you need new protein(s) or more of your current protein(s), call us to find how our capabilities and expertise can be your new advantage.
Senior Biochemist Joins Helix!
Jennifer Arruda brings her talent to Helix Bio. Jennifer established her career later in life and found her passion in protein biochemistry and structural biology.
She brings to us 14 years’ experience in both academia and industry. Her experiences span areas such as protein expression in multiple expression systems, microbial fermentation, protein purification and assay development.
